RHÖN-KLINIKUM Aktiengesellschaft/€RHK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM AG is a German healthcare provider operating five hospital sites: Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen, Universitätsklinikum Marburg (UKGM), and Zentralklinik Bad Berka. The company offers inpatient and outpatient medical services, treating approximately 913,000 patients annually. Headquartered in Bad Neustadt a. d. Saale, Germany, RHÖN-KLINIKUM AG employs over 18,700 individuals. In 2020, Asklepios Kliniken GmbH & Co. KGaA acquired a majority stake in RHÖN-KLINIKUM AG, leading to a strategic partnership while maintaining RHÖN-KLINIKUM AG's independence within the Asklepios group. The company focuses on cross-sector healthcare delivery, digital transformation, and sustainability initiatives, including plans to achieve CO₂-neutrality in Scope 1 and Scope 2 emissions by 2040.
- Ticker
- €RHK
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 19,120
- Headquarters
- Bad Neustadt an der Saale, Germany
- Website
- www.rhoen-klinikum-ag.com
RHK Metrics
BasicAdvanced
€977M
23.29
€0.62
-
€0.20
1.37%
Price and volume
Market cap
€977M
52-week high
€15.90
52-week low
€11.70
Average daily volume
2.6K
Dividend rate
€0.20
Financial strength
Current ratio
2.686
Quick ratio
1.172
Long term debt to equity
0.081
Total debt to equity
0.082
Interest coverage (TTM)
19.41%
Profitability
EBITDA (TTM)
110.774
Gross margin (TTM)
12.72%
Net profit margin (TTM)
2.04%
Operating margin (TTM)
2.73%
Effective tax rate (TTM)
22.66%
Revenue per employee (TTM)
€110,000
Management effectiveness
Return on assets (TTM)
1.90%
Return on equity (TTM)
3.24%
Valuation
Price to earnings (TTM)
23.285
Price to revenue (TTM)
0.476
Price to book
0.74
Price to tangible book (TTM)
0.85
Dividend yield (TTM)
1.37%
Forward dividend yield
1.37%
Growth
Revenue change (TTM)
5.23%
Earnings per share change (TTM)
10.06%
3-year revenue growth (CAGR)
6.24%
10-year revenue growth (CAGR)
4.76%
3-year earnings per share growth (CAGR)
8.57%
10-year earnings per share growth (CAGR)
-8.45%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
-12.94%
Bulls say / Bears say
In the first half of 2026, revenue rose 3.6% to €863.6 million, EBITDA increased to €57.0 million from €46.7 million and net profit reached €22.5 million from €14.7 million. Patient numbers grew 9%, and management expects full-year EBITDA of €110–125 million. (RHÖN-KLINIKUM AG)
The group is expanding specialist services and regional partnerships, while a new €6 million hybrid operating theatre at Frankfurt (Oder) adds capacity for complex vascular and cardiac procedures. These investments could help strengthen its service offer and patient appeal. (RHÖN-KLINIKUM AG, RHÖN-KLINIKUM AG)
RHÖN integrated a six-practice orthopaedic and specialist medical group into its Bad Neustadt network in the first quarter. The deal broadens outpatient access and gives the company an additional route to grow regional care. (EQS News)
The company says new hospital and health-insurance legislation will put hospitals under greater short-term financial pressure, and it cannot yet reliably estimate the combined effect on its business. That uncertainty leaves its 2026 forecast exposed to changes in reimbursement and regulation. (RHÖN-KLINIKUM AG)
The €850 million UKGM investment programme has advanced slowly, and RHÖN says the university hospital must fund about 30% of the investment costs itself. If the dispute with Hesse over funding is not resolved, the company may consider terminating the agreement, putting planned investment and financing at risk. (Gießener Anzeiger)
Asklepios has requested a squeeze-out of minority shareholders, who would have to transfer their shares for cash if the required shareholder vote and registration proceed. The proposed payment amount has not been disclosed in the announcement, leaving minority investors exposed to a forced exit at a price they cannot yet assess. (Asklepios)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
RHK Financial Performance
Revenues and expenses
RHK Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.